Targeted therapy prolongs life in patients with HER2-positive breast cancer

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumours are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Centre. Blackwell presented the findings today at the CTRC-AACR San Antonio Breast Cancer Symposium...

Read the whole article on

More from